Skip to main content
Journal Article

The shifting treatment paradigm of metastatic renal cell carcinoma

Nature Reviews Urology (2022) 19(11) 631-632
DOI: 10.1038/s41585-022-00651-9
7Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.
Get full text

References Powered by Scopus

Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma

New England Journal of Medicine
1208Citations
N/AReaders
Get full text

Systemic therapy for metastatic renal-cell carcinoma

New England Journal of Medicine
987Citations
N/AReaders
Get full text

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

JNCCN Journal of the National Comprehensive Cancer Network
404Citations
N/AReaders
Get full text
View more at Scopus

Cited by Powered by Scopus

Non-coding RNAs in renal cell carcinoma: Implications for drug resistance

Biomedicine and Pharmacotherapy
8Citations
N/AReaders
Get full text

Beyond the knife: strategic patient selection for cytoreductive nephrectomy

Current Opinion in Urology
2Citations
N/AReaders
Get full text

Radiomics Correlation to CD68+ Tumor-Associated Macrophages in Clear Cell Renal Cell Carcinoma

Oncology (Switzerland)
2Citations
N/AReaders
Get full text
View more at Scopus

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ged, Y., Markowski, M. C., Singla, N., & Rowe, S. P. (2022). The shifting treatment paradigm of metastatic renal cell carcinoma. Nature Reviews Urology, 19(11), 631–632. https://doi.org/10.1038/s41585-022-00651-9

Readers' Seniority

Tooltip

Researcher 2

100%

Save time finding and organizing research with Mendeley

Sign up for free